The b-hydroxybutyrate receptor HCA 2 activates a neuroprotective subset of macrophages

Nature Communications

Volumn 5, Issue , 2014, Pages

  Rahman, Mahbubur ^a   Muhammad, Sajjad ^b   Khan, Mahtab A ^a   Chen, Hui ^a   Ridder, Dirk A ^a   Müller Fielitz, Helge ^a   Pokorná, Barbora ^b   Vollbrandt, Tillman ^a   Stölting, Ines ^a   Nadrowitz, Roger ^a   Okun, Jürgen G ^c   Offermanns, Stefan ^d,e   Schwaninger, Markus ^a,f  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; FATTY ACID; GLUCOSE; GPR 109A; IMMUNOGLOBULIN G; KETONE BODY; LIPID; NICOTINIC ACID; PROSTAGLANDIN D2; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; 3 HYDROXYBUTYRIC ACID; G PROTEIN COUPLED RECEPTOR; HCAR2 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; NICOTINIC RECEPTOR;

BRAIN; DATA SET; DISEASE PREVALENCE; ENZYME ACTIVITY; INFILTRATION; KETONE; NEUROLOGY; NUMERICAL MODEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; BRAIN; BRAIN BLOOD FLOW; CELL INFILTRATION; CELL POPULATION; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; KETOGENESIS; KETOGENIC DIET; LASER DOPPLER FLOWMETRY; LIMIT OF QUANTITATION; LIPID BLOOD LEVEL; MACROPHAGE; MACROPHAGE FUNCTION; MALE; MICROSCOPE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOCYTE; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; SENSORIMOTOR FUNCTION; SURGICAL EQUIPMENT; TREATMENT RESPONSE; URINARY EXCRETION; AGONISTS; ANIMAL; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM;

3-HYDROXYBUTYRIC ACID; ANIMALS; BRAIN; KETOGENIC DIET; MACROPHAGES; MICE; MICE, KNOCKOUT; MONOCYTES; NEUROPROTECTIVE AGENTS; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; STROKE;

EID: 84901325457     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4944     Document Type: Article

References (67)

1. Dupuis, L., Pradat, P. F., Ludolph, A. C. & Loeffler, J. P. Energy metabolism in amyotrophic lateral sclerosis. Lancet. Neurol. 10, 75-82 (2011).
2. Exner, N., Lutz, A. K., Haass, C. & Winklhofer, K. F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. Embo J. 31, 3038-3062 (2012).
3. Kruyt, N. D., Biessels, G. J., DeVries, J. H. & Roos, Y. B. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat. Rev. Neurol. 6, 145-155 (2010).
4. Prins, M. L. Cerebral metabolic adaptation and ketone metabolism after brain injury. J. Cereb. Blood Flow Metab. 28, 1-16 (2008).
5. Suzuki, M. et al. Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia. Jpn J. Pharmacol. 89, 36-43 (2002). (Pubitemid 34618607)
6. Puchowicz, M. A. et al. Neuroprotection in diet-induced ketotic rat brain after focal ischemia. J. Cereb. Blood Flow Metab. 28, 1907-1916 (2008).
7. Tieu, K. et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Invest. 112, 892-901 (2003). (Pubitemid 38063747)
8. Lutas, A. & Yellen, G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci. 36, 32-40 (2013).
9. Stafstrom, C. E. & Rho, J. M. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front. Pharmacol. 3, 59 (2012).
10. Gasior, M., Rogawski, M. A. & Hartman, A. L. Neuroprotective and diseasemodifying effects of the ketogenic diet. Behav. Pharmacol. 17, 431-439 (2006). (Pubitemid 44325805)
11. Senior, B. & Loridan, L. Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man. Nature 219, 83-84 (1968).
12. Taggart, A. K. P. et al. D)-{beta}-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280, 26649-26652 (2005). (Pubitemid 41040696)
13. Tunaru, S. et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9, 352-355 (2003). (Pubitemid 36362793)
14. Lukasova, M., Hanson, J., Tunaru, S. & Offermanns, S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol. Sci. 32, 700-707 (2011).
15. Miller, C. L. & Dulay, J. R. The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. Brain Res. Bull. 77, 33-41 (2008).
16. Lauring, B. et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med. 4, 148-115 (2012).
17. Hanson, J. et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Invest. 120, 2910-2919 (2010).
18. Lubjuhn, J. et al. Functional testing in a mouse stroke model induced by occlusion of the distal middle cerebral artery. J. Neurosci. Methods 184, 95-103 (2009).
19. Gliem, M. et al. Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann. Neurol. 71, 743-752 (2012).
20. Gordon, S. & Taylor, P. R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953-964 (2005). (Pubitemid 41746764)
21. Duffield, J. S. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115, 56-65 (2005). (Pubitemid 40385505)
22. Taniguchi, H. et al. Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. J. Neurosci. 27, 4303-4312 (2007). (Pubitemid 46640702)
23. Zhao, G. et al. Pivotal role of reactive oxygen species in differential regulation of lipopolysaccharide-induced prostaglandins production in macrophages. Mol. Pharmacol. 83, 167-178 (2013).
24. Knowles, H. J., te Poele, R. H., Workman, P. & Harris, A. L. Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol. 71, 646-656 (2006). (Pubitemid 43121998)
25. Meyers, C. D., Liu, P., Kamanna, V. S. & Kashyap, M. L. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: An in vitro model of the niacin flush. Atherosclerosis 192, 253-258 (2007). (Pubitemid 46726325)
26. Song, W. -L. et al. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J. Biol. Chem. 283, 1179-1188 (2008).
27. Hankes, L. V. et al. Effect of Huntington's and Alzheimer's diseases on the transport of nicotinic acid or nicotinamide across the human blood-brain barrier. Adv. Exp. Med. Biol. 294, 675-678 (1991).
28. Iadecola, C., Sugimoto, K., Niwa, K., Kazama, K. & Ross, M. E. Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice. J. Cereb. Blood Flow Metab. 21, 1436-1441 (2001). (Pubitemid 33117184)
29. Zou, L. Y., Cheung, R. T., Liu, S., Li, G. & Huang, L. Melatonin reduces infarction volume in a photothrombotic stroke model in the wild-type but not cyclooxygenase-1-gene knockout mice. J. Pineal Res. 41, 150-156 (2006). (Pubitemid 44141750)
30. Cheung, R. T., Pei, Z., Feng, Z. H. & Zou, L. Y. Cyclooxygenase-1 gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model. Neurosci. Lett. 330, 57-60 (2002). (Pubitemid 35245769)
31. Aritake, K., Kado, Y., Inoue, T., Miyano, M. & Urade, Y. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J. Biol. Chem. 281, 15277-15286 (2006). (Pubitemid 43855117)
32. Gille, A., Bodor, E. T., Ahmed, K. & Offermanns, S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48, 79-106 (2008). (Pubitemid 351738150)
33. Kashiwaya, Y. et al. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc. Natl Acad. Sci. USA 97, 5440-5444 (2000). (Pubitemid 30313737)
34. Masuda, R., Monahan, J. W. & Kashiwaya, Y. D-beta-hydroxybutyrate is neuroprotective against hypoxia in serum-free hippocampal primary cultures. J. Neurosci. Res. 80, 501-509 (2005). (Pubitemid 40780810)
35. Noh, H. S. et al. Acetoacetate protects neuronal cells from oxidative glutamate toxicity. J. Neurosci. Res. 83, 702-709 (2006). (Pubitemid 43384863)
36. Bough, K. J. et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. 60, 223-235 (2006). (Pubitemid 44182397)
37. Mildner, A. et al. Microglia in the adult brain arise from Ly-6ChiCCR2? monocytes only under defined host conditions. Nat. Neurosci. 10, 1544-1553 (2007). (Pubitemid 350175884)
38. Chen, H. et al. Hydroxy-carboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J. Clin. Invest 124, 2188-2192 (2014).
39. Kostylina, G., Simon, D., Fey, M. F., Yousefi, S. & Simon, H. U. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell. Death. Differ. 15, 134-142 (2008). (Pubitemid 350286181)
40. Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 3037-3047 (2007). (Pubitemid 350179569)
41. Song, W. L. et al. Niacin and biosynthesis of PGD(2) by platelet COX-1 in mice and humans. J. Clin. Invest. 122, 1459-1468 (2012).
42. Rajakariar, R. et al. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15- deoxyDelta12 14 PGJ2. Proc. Natl Acad. Sci. USA 104, 20979-20984 (2007).
43. Masuda, Y. et al. Protective effect of prostaglandins D2, E1 and I2 against cerebral hypoxia/anoxia in mice. Naunyn Schmiedebergs Arch. Pharmacol. 334, 282-289 (1986). (Pubitemid 17056518)
44. Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I[kappa]B kinase. Nature 403, 103-118 (2000).
45. Herrmann, O. et al. IKK mediates ischemia-induced neuronal cell death. Nat. Med. 11, 1322-1329 (2005). (Pubitemid 41752913)
46. Zandi-Nejad, K. et al. The role of HCA2 (GPR109A) in regulating macrophage function. FASEB J. 27, 4366-4374 (2013).
47. Ridder, D. A. & Schwaninger, M. In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease. Exp. Neurol. 238, 133-137 (2012).
48. Zhao, X. et al. Neuronal PPARg deficiency increases susceptibility to brain damage after cerebral ischemia. J. Neurosci. 29, 6186-6195 (2009).
49. Kim, E. H. & Surh, Y. J. The role of 15-deoxy-delta(12,14)- prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis. Biochem. Pharmacol. 76, 1544-1553 (2008).
50. Lukasova, M., Malaval, C., Gille, A., Kero, J. & Offermanns, S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest. 121, 1163-1173 (2011).
51. Prinz, M., Priller, J., Sisodia, S. S. & Ransohoff, R. M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 14, 1227-1235 (2011).
52. Butovsky, O. et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 122, 3063-3087 (2012).
53. Biju, K. et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol. Ther. 18, 1536-1544 (2010).
54. Shehadah, A. et al. Niaspan treatment induces neuroprotection after stroke. Neurobiol. Dis. 40, 277-283 (2010).
55. Chen, J. et al. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann. Neurol. 62, 49-58 (2007). (Pubitemid 47235280)
56. Fisher, C. M. The use of anticoagulants in cerebral thrombosis. Neurology 8, 311 (1958).
57. Habenicht, J. [Early therapy of apoplexy with sodium nicotinate]. Dtsch. Gesundheitsw. 8, 601-605 (1953).
58. Furtado, D. Nicotinic acid in cerebral thrombosis. Lancet 239, 602 (1942).
59. Anderson, W. D. & Kubicek, W. G. Effects of betahistine HCl, nicotinic acid, and histamine on basilar blood flow in anesthetized dogs. Stroke 2, 409-415 (1971).
60. Scheinberg, P. The effect of nicotinic acid on the cerebral circulation, with observations on extracerebral contamination of cerebral venous blood in the nitrous oxide procedure for cerebral blood flow. Circulation 1, 1148-1154 (1950).
61. Tang, H., Lu, J. Y., Zheng, X., Yang, Y. & Reagan, J. D. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem. Biophys. Res. Commun. 375, 562-565 (2008).
62. Offermanns, S., Colletti, S. L., Lovenberg, T. W., Semple, G. & Wise, A. AP IJ. international union of basic and clinical pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev. 63, 269-290 (2011).
63. Shen, H. C. & Colletti, S. L. High-affinity niacin receptor GPR109A agonists. Annu. Rep. Med. Chem. 45, 72-94 (2010).
64. Langenbach, R. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83, 483-492 (1995).
65. Bargiotas, P. et al. Connexin 36 promotes cortical spreading depolarization and ischemic brain damage. Brain Res. 1479, 80-85 (2012).
66. Muhammad, S. et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28, 12023-12031 (2008).
67. Gelderblom, M. et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40, 1849-1857 (2009).